focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

FDA issues new rule to ensure safety of infant formula

Thu, 06th Feb 2014 16:31

Feb 6 (Reuters) - The U.S. Food and Drug Administrationproposed a new rule to better regulate and set safety standardsin the manufacture of infant formula products.

The interim final rule amends the FDA's quality controlprocedures, notification requirements for new formulas andchanges to formulas, and requirements concerning whatmanufacturing records and reports must be maintained.

The rule also establishes good manufacturing practices forinfant formula, including testing for contamination from harmfulbacteria such as Salmonella.

"This rule will help to prevent adulteration in infantformula and ensure infant formula supports normal, physicalgrowth," Michael Taylor, FDA's deputy commissioner for Foods andVeterinary Medicine, said in a statement. ()

He noted that many families rely on infant formula as eitherthe sole source of nutrition or an integral part of an infant'sdiet through the first year.

The U.S. health regulator has amped up its efforts tosafeguard public health with several significant measuresannounced over the past few months, including proposed rulescalling for better safety of products such as antibacterialsoaps, apple juice and imported food.

The FDA said the new rule only applied to infant formulasfor use by healthy infants without unusual medical or dietaryproblems.

The regulator will accept and review comments from thepublic on the rule for 45 days, it said.

Related Shares

More News
21 May 2024 11:23

AstraZeneca aims for $80 bln in total revenue by 2030

Sees $80 bln in 2030 revenue by 2030 *

21 May 2024 08:49

GSK's depemokimab asthma treatment meets endpoints in latest trials

(Alliance News) - GSK PLC on Tuesday announced positive results from trials of depemokimab, an "ultra-long-acting biologic" that could simplify treatm...

21 May 2024 07:21

GSK reports promising results from asthma treatment trials

(Sharecast News) - GSK announced promising results from phase three clinical trials evaluating the efficacy and safety of depemokimab in treating seve...

20 May 2024 16:11

IN BRIEF: GSK executive buys GBP20,026 worth shares

GSK PLC - London-based pharmaceuticals firm - Senior Vice President, Global Communications & Chief Executive Office, Sally Jackson, buys 1,120 shares ...

17 May 2024 17:38

London's FTSE nudges lower for week after record run

Haleon falls after GSK offloads remaining stake *

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.